Amgen and UCB's romosozumab shows improvements in bone density

9 September 2022

Belgium’s biggest pharma firm UCB (Euronext: UCB) and US biotech giant Amgen (Nasdaq: AMGN) today presented abstracts of three post-hoc analyses focusing on 3D modelling techniques that highlight significant cortical and trabecular bone improvements in patients treated with romosozumab.

The data were presented along with additional 17 abstracts, at the American Society for Bone and Mineral Research (ASBMR) 2022 Annual Congress, taking place from 9th – 12th September in Austin, Texas, USA.

Trade-named Evenity, the drug was approved for the treatment of osteoporosis first in the USA in 2016, and in Europe and Japan in 2019. Amgen reported full-year 2021 sales of $530 million for Evenity, a rise of 51%. UCB’s sales of the drug for first-half 2022 were around $9 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK